HuGE Literature Finder
|
||
Records 1-8
|
Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype-guided doses in renal transplantation patients.
British journal of clinical pharmacology 2019 May . Anutrakulchai Sirirat, Pongskul Cholatip, Kritmetapak Kittrawee, Limwattananon Chulaporn, Vannaprasaht Su |
|
The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients.
Archives of medical science : AMS 2018 Oct 14 (6): 1416-1423. Belohlavkova Petra, Vrbacky Filip, Voglova Jaroslava, Racil Zdenek, Zackova Daniela, Hrochova Katerina, Malakova Jana, Mayer Jiri, Zak Pav |
|
Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients.
Pharmacogenetics and genomics 2014 Dec 24 (12): 597-606. Kuypers Dirk R J, de Loor Henriette, Naesens Maarten, Coopmans Tamara, de Jonge Hyl |
|
Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus.
Journal of gastroenterology and hepatology 2014 Jan 29 (1): 60-6. Hirai Fumihito, Takatsu Noritaka, Yano Yutaka, Satou Yuhou, Takahashi Haruhiko, Ishikawa Satoshi, Tsurumi Kozue, Hisabe Takashi, Matsui Toshiyu |
|
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.
Breast cancer research and treatment 2012 Jul 134 (1): 401-10. Hertz Daniel L, Motsinger-Reif Alison A, Drobish Amy, Winham Stacey J, McLeod Howard L, Carey Lisa A, Dees E Clai |
|
CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients.
Transplantation 2010 Dec 90 (12): 1394-400. Min Sang-Il, Kim Seong Yup, Ahn Sang Hyun, Min Seung-Kee, Kim Si Hwa, Kim Yon Su, Moon Kyung Chul, Oh Jung Mi, Kim Sang Joon, Ha Jongw |
|
Optimization of initial tacrolimus dose using pharmacogenetic testing.
Clinical pharmacology and therapeutics 2010 Jun 87 (6): 721-6. Thervet E, Loriot M A, Barbier S, Buchler M, Ficheux M, Choukroun G, Toupance O, Touchard G, Alberti C, Le Pogamp P, Moulin B, Le Meur Y, Heng A E, Subra J F, Beaune P, Legendre |
|
Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
Arthritis and rheumatism 2004 Jul 50 (7): 2202-10. Takada Kazuki, Arefayene Million, Desta Zeruesenay, Yarboro Cheryl H, Boumpas Dimitrios T, Balow James E, Flockhart David A, Illei Gabor |
- Page last reviewed:Jul 30, 2019
- Page last updated:Dec 12, 2019
- Content source: